NCT06991361View on ClinicalTrials.gov

Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 1, 2028

Study Completion Date

December 1, 2028

Conditions

Graft Versus Host Disease (cGvHD)

Interventions

BIOLOGICAL

EVE-Treg

Ex Vivo-Expanded (EVE) Regulatory T cells.

All Listed Sponsors

lead

Leslie Kean

OTHER